You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

nandrolone decanoate - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for nandrolone decanoate and what is the scope of freedom to operate?

Nandrolone decanoate is the generic ingredient in two branded drugs marketed by Woodward Specl, Abraxis Pharm, Am Regent, Epic Pharma Llc, and Watson Labs, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for nandrolone decanoate
US Patents:0
Tradenames:2
Applicants:5
NDAs:11

US Patents and Regulatory Information for nandrolone decanoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Woodward Specl DECA-DURABOLIN nandrolone decanoate INJECTABLE;INJECTION 013132-001 Jun 12, 1986 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Woodward Specl DECA-DURABOLIN nandrolone decanoate INJECTABLE;INJECTION 013132-002 Jun 12, 1986 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Woodward Specl DECA-DURABOLIN nandrolone decanoate INJECTABLE;INJECTION 013132-003 Jun 12, 1986 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Abraxis Pharm NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 088290-001 Oct 3, 1983 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Abraxis Pharm NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 088317-001 Oct 14, 1983 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Am Regent NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 091252-001 Aug 30, 2010 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Nandrolone Decanoate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Nandrolone decanoate, an anabolic steroid primarily used for medical and performance-enhancing purposes, presents a complex investment landscape. The drug’s legal use in hormone therapy and its controversial status in sports doping intersect with emerging markets, regulatory environments, and counterfeit risks. This report provides a comprehensive analysis of its market dynamics, regulatory considerations, investment opportunities, and financial trajectories, informing stakeholders on current and future prospects.


What is Nandrolone Decanoate?

Attribute Details
Chemical Name Nandrolone decanoate (also known as Deca-Durabolin)
Molecular Formula C28H44O3
Pharmacological Class Anabolic-androgenic steroid (AAS)
Primary Uses Medical treatments for anemia, osteoporosis, muscle wasting (e.g., HIV/AIDS), delayed puberty
Abuse & Illicit Use Performance enhancement in sports, bodybuilding

Market approval status varies globally, distributed in regulated pharmaceutical markets and often diverted into black markets.


Market Dynamics

Global Market Size & Growth

Parameter Value & Trends Sources
Size (2022) Estimated $300 million Industry reports[1]
Annual CAGR (2018–2022) ~4.5% Euromonitor[2]
Forecast (up to 2030) ~$450 million Market Research Future[3]

Key Market Segments

Segment Description Growth Drivers
Medical Use Treatment of anemia, osteoporosis Aging populations, hormone therapy demand
Athletic & Bodybuilding Performance enhancement Rising fitness trends, illegal doping markets
Counterfeit & Black Market Unregulated supply Regulatory crackdowns, enforcement challenges

Regional Market Distribution

Region Market Share (2022) Key Factors
North America 45% High medical demand, doping prevalence
Europe 30% Regulatory restrictions, medical use
Asia-Pacific 15% Emerging clinics, black market activity
Rest of World 10% Varies by regulation

Legal and Regulatory Landscape

Region Status Major Regulations Impact
U.S. Schedule III substance DEA Controlled Substance Act Prescriptions only, strict penalties for illicit use
EU Controlled substance EU Narcotic Precursors Regulations Licensing required, import/export restrictions
Asia (India, China) Varies Regulations evolving Easier access, higher black-market activity
Emerging Markets Often less regulated Weak enforcement Higher potential for diversion and counterfeit products

Regulatory Trends & Challenges

  • Enhanced enforcement against counterfeit and illicit trafficking.
  • Prescription regulation tightening affecting legitimate pharmaceutical sales.
  • Growth in online distribution complicates compliance.
  • Legal status influencing R&D, manufacturing, and investment strategies.

Market Drivers & Restraints

Drivers Details Impact
Aging Population Increased hormone therapy needs Expanding legitimate pharma sector
Athletic Doping Persistent demand in illicit sports markets Sustains black-market economies
Medical Innovation New indications and formulations Opens new revenue pathways
Regulatory Scrutiny Stricter controls Limits supply, raises costs
Restraints Details Impact
Legal Risks Severe penalties for illicit trafficking Reduced legal supply, increased illicit activity
Health Concerns Side effects, abuse potential Regulatory pushback
Market Saturation Limited room for growth in mature markets Pricing pressures, shrinking margins

Investment Opportunities & Risks

Opportunities

  • Legal pharmaceutical manufacturing for approved medical indications.
  • Innovative drug delivery systems (e.g., depot formulations) to extend market share.
  • Emerging markets with lax regulation and rising demand.
  • Black market dynamics offering high-margin opportunities, albeit with legal risks.
  • R&D investments targeting new indications, e.g., burn rehabilitation or muscle degenerative diseases.

Risks

  • Regulatory bans or restrictions leading to market withdrawal.
  • Prosecution & legal exposure due to trafficking or misuse.
  • Intense competition from other anabolic steroids and hormone therapies.
  • Counterfeit proliferation undermining brand integrity.
  • Public health policy shifts reducing acceptability and access.

Financial Trajectory & Revenue Projections

Parameter 2022 2025 2030 Notes
Market Size (USD) $300M $375M $450M Growth driven by medical demand and emerging markets
Average Price per Unit $10–$15 $8–$12 $7–$10 Price decline anticipated due to generic competition
Manufacturing Costs $4–$6 $3–$5 $3–$4 Process optimization expected
Profit Margin ~40% 45% 45–50% Potential increase with process innovations
Key Revenue Streams Pharmaceutical sales, illicit markets Pharma, online illicit supply Diversified across channels

Note: Revenue projections assume extrication from illicit trade constraints and regulatory clearance for medical use.


Comparison with Similar Anabolic Steroids

Steroid Market Size (2022) Legal Status Medical Use Illicit Use Price Range (per 10 ml)
Oxandrolone ~$150M Schedule III Yes Yes $15–$25
Stanozolol ~$100M Controlled Yes Yes $10–$20
Methenolone ~$80M Controlled Yes Yes $8–$12
Nandrolone Decanoate $300M Schedule III Yes Yes $10–$15

Deep Dive: Business & Investment Strategies

Manufacturing & Supply Chain Considerations

  • Patent & IP: Limited patent exclusivity for generic formulations; key in maintaining margins.
  • Quality Assurance: Critical in pharmaceutical sales, must adhere to cGMP standards.
  • Supply Chain Risks: Counterfeit infiltration, import/export restrictions.

Market Entry Strategies

  • Medical Focus: Obtain regulatory approval, leverage hospital and clinic channels.
  • Black Market: Engage with established networks cautiously, aware of legal implications.
  • Online Platforms: Tap into direct-to-consumer online markets, complying with applicable laws.

Partnership & Licensing Opportunities

  • Collaborations with local distributors for emerging markets.
  • Licensing agreements for formulations or new indications.
  • Engagement with regulatory agencies for accelerated approvals.

FAQs

1. What are the key factors influencing investment in nandrolone decanoate?

Regulatory status, market size, demand in medical and illicit sectors, and the ability to navigate legal and safety issues.

2. How do regulatory restrictions impact market growth?

Stringent controls reduce legal sales but can bolster illicit markets, affecting overall revenue stability.

3. What potential does the black-market trade hold?

High margins exist; however, legal risks, health concerns, and law enforcement efforts threaten sustainability.

4. How is innovation affecting its market trajectory?

New formulations, delivery methods, and potential novel therapeutic indications could expand the legitimate market.

5. What are the key risks for investors?

Legal enforcement, reputation risks, market saturation, and counterfeit proliferation.


Key Takeaways

  • Market worth is approximately $300 million globally, with steady growth driven by medical needs and illicit demand.
  • Regulatory environment is complex; strict controls limit legitimate sales but incentivize black-market activity.
  • Investment opportunities exist in legalized pharmaceutical manufacturing, especially in emerging markets and novel formulations.
  • Risks include legal penalties, counterfeit infiltration, and market saturation.
  • Financial projections suggest a compound annual growth rate of approximately 4.5% up to 2030, with margins improving through process efficiencies and market expansion.

References

[1] Industry Reports on Anabolic Steroid Market, 2022

[2] Euromonitor International, “Global Market Trends,” 2022

[3] Market Research Future, “Pharmaceuticals in Emerging Markets,” 2021


Disclaimer: This analysis is for informational purposes only and not financial or legal advice. Stakeholders should conduct thorough due diligence considering local laws and market conditions before engaging in activities related to nandrolone decanoate.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.